Bio-Path Holdings, Inc. (BPTH) Year-over-year earnings per share growth for the last twelve months

Geopolitical supply chain disruptions have pressured Bio-Path Holdings (BPTH), as reflected in the GURU.Markets terminal line chart regarding quarterly EPS changes, where 0.00 shows the current metric volume. While BP1001 gene-silencing developments provide positive momentum, the risk of equity dilution from frequent secondary offerings and delays in leukemia tests maintain high uncertainty.

For Bio-Path Holdings (BPTH), which is developing an innovative liposomal cancer therapy platform, quarterly EPS serves as an indicator of the scientific activity's ability to generate real profit. By analyzing the quarterly EPS chart, an investor assesses the growth rate of net income per share, allowing them to differentiate an active growth phase from market overheating and avoid overpaying for the asset.